A VAD or Ventricular Assist Device is an electromechanical pump that is implanted inside a person’s chest for assisting cardiac circulation, which is used to either to partially or to completely replace the function of a weakened heart. A VAD is dissimilar from an artificial cardiac pacemakers. An artificial cardiac pacemaker replaces the weak heart permanently, whereas a VAD works with the heart to help it pump more blood with less work. It does this by continuously taking blood from the ventricle and moving it to the aorta, which then delivers oxygen-rich blood throughout the body. Some of the VADs are used for short term, typically for patients recovering from myocardial infarction and for patients recovering from heart surgery; and some are used for long-term, which includes for patients suffering from advanced congestive heart failure. Moreover. These VADs are designed to assist either right ventricle or the left ventricle or to assist both ventricles. Among these, LVAD implantations are huge in number and accounted for highest market share due to a high number of patients suffering from left ventricular disease. Surgeons implant this device as a treatment option for severe heart conditions such as heart failures, and chronic cardiac function disorders. The VAD mechanical pump has both internal and external components. The actual pump sits on or next to heart’s ventricle with a tube attached that routes the blood to aorta. A cable called driveline extends from the pump, out through the skin, and connects the pump to a controller and power sources worn outside the body. Ventricular assist devices are used in those patients who are suffering with class III and class IV advanced heart diseases as per New York Heart Association (NYHA) and patients who are awaiting for not suitable for heart transplantation.
Some of the key driving factors attributing to the growth of this include increasing number of patients with cardiovascular diseases such as hypertension, heart failures and coronary artery diseases, and shortage of number of heart donors. In addition, changing lifestyle, alcohol consumption, growing obesity and smoking further propelling the market growth, as these factors increase the bold glucose and lipid levels, which results in serious cardiovascular diseases. According to American Heart Association publication, it has been estimated that in the US alone approximately 5.5 million people suffered from heart failure in 2013 and 300,000 die each year because of heart failure. The market for VAD is expected to reach around USD 2.5 billion by 2022, growing at a CAGR of 15.2% during the forecast period of 2016e to 2022f. However, there are certain restraining factors which could hamper the growth of the market, which includes, high costs associated with the VAD implantation compared to other therapies available for CVD diseases and other serious complications such as severe bleeding. Immunosuppression, etc.
Geographically, North America is leading contributor to the market and is expected to retain its position during the forecast period. Nonetheless, the market for Asia-Pacific region is expected to grow at a faster rate owing to increasing prevalence of CVD diseases, growing awareness among the population, improving healthcare infrastructure, rise in healthcare spending, and favorable government policies.
- Heart Ware International Inc.
- St Jude Medical
- Berlin Heart GmbH
- Apaxis, Inc.
- Sun Medical Technology Research
- Terumo Corporation